Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.

被引：27

作者：

Balar, Arjun Vasant

Galsky, Matt D.

Loriot, Yohann

Dawson, Nancy Ann

Necchi, Andrea

Srinivas, Sandy

Joseph, Richard Wayne

Vaishampayan, Ulka N.

Sridhar, Srikala S.

Quinn, David I.

Drakaki, Alexandra

Duran, Ignacio

Rosenberg, Jonathan E.

Powles, Thomas

Hoffman-Censits, Jean H.

Cui, Na

Mariathasan, Sanjeev

Thastrom, Ann Christine

Abidoye, Oyewale O.

Bajorin, Dean F.

机构：

[1] NYU, Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA

[2] Icahn Sch Med Mt Sinai, New York, NY USA

[3] Univ Paris Sud, Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[4] Lombardi Comprehens Canc Ctr, Washington, DC USA

[5] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[6] Stanford Univ, Med Ctr, Stanford, CA 94305 USA

[7] Mayo Clin, Jacksonville, FL 32224 USA

[8] Karmanos Canc Inst, Detroit, MI USA

[9] Princess Margaret Canc Ctr, Toronto, ON, Canada

[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[11] Westwood Rheumatol, Los Angeles, CA USA

[12] Hosp Univ Virgen Rocio, Seville, Spain

[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[14] Barts Hlth, Barts Canc Inst, London, England

[15] Royal Free London NHS Fdn Trust, London, England

[16] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[17] Genentech Inc, South San Francisco, CA USA

[18] Genentech Inc, San Mateo, CA USA

[19] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 18期

关键词：

D O I：

10.1200/JCO.2016.34.18_suppl.LBA4500

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4500

引用

页数：2